Secondary analysis of GAP70+ (704 adults aged ≥70 with advanced cancer starting systemic therapy): patient-reported cognitive adverse events exceeded clinician-graded ones at every time point, e.g. 19% vs 0.48% at 4–6 weeks and 22% vs 0.44% at 6 months (P<.001).
Secondary analysisn = 704
Alieldin et al. Prevalence of patient-reported and clinician-graded cognitive symptomatic adverse events in older patients with advanced cancer